Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

1. Earlier age at menopause was associated with faster global and episodic memory decline, earlier Alzheimer disease diagnosis, and faster white matter hyperintensity accumulation in a 2,603-woman cohort followed for up to 18 years, with structural associations strongest among women with spontaneous menopause.

2. The associations do not establish that menopause causes Alzheimer disease or that extending estrogen exposure would prevent decline, and should not be read as support for hormone therapy as dementia prevention; instead, menopause timing may function as a midlife marker for closer monitoring of modifiable brain-health risk factors.

Age at menopause was examined in relation to several measures of brain health and aging in a JAMA Network Open study published August 25th. Researchers followed 2,603 women from the Religious Orders Study and Rush Memory and Aging Project for up to 18 years, drawing on annual cognitive assessments, neuropathological evaluations at autopsy in 1,287 women, and serial magnetic resonance imaging in 774 women. The study examined whether menopause age and type were associated with cognitive decline, clinical Alzheimer disease, neuropathology, and changes in brain structure. The researchers found that women who experienced menopause earlier in life had faster declines in global cognition and episodic memory and were diagnosed with clinical Alzheimer disease earlier. The strength of this association varied by menopause type, with the relationship with Alzheimer disease diagnosis somewhat stronger among women who underwent surgical menopause. Earlier menopause was also associated with faster accumulation of white matter hyperintensities on MRI, particularly among women with spontaneous menopause, and this association became more pronounced with advancing age. No similar association was observed among women with surgical menopause. In contrast, the relationship between menopause timing and total brain volume loss was comparatively modest. The neuropathological analyses also evaluated Alzheimer disease pathology alongside other brain changes, including vascular and degenerative pathologies, offering insight into whether menopause timing may be related to specific pathways of brain aging rather than overall brain deterioration alone.

The long-term design of the Rush aging studies provides important context for interpreting these findings, with annual cognitive evaluations and, for many participants, brain imaging and neuropathologic assessment dating back to the early 1990s. Importantly, these observational associations do not demonstrate that menopause itself causes Alzheimer disease or that extending estrogen exposure would prevent cognitive decline. They also should not be interpreted as evidence to prescribe menopausal hormone therapy for dementia prevention, an area in which evidence remains uncertain. Instead, menopause timing may function as a midlife marker that helps identify women who warrant closer attention to modifiable cardiovascular and neurologic risk factors. The findings add reproductive history to a growing list of information that may eventually improve individualized assessment of healthy brain aging. In practice, age at menopause and whether it occurred spontaneously or surgically could potentially become part of a broader midlife health history, considered alongside established risk factors such as blood pressure, lipids, and glucose. This may be particularly relevant given the study’s findings involving white matter hyperintensities, which are also associated with vascular risk factors such as hypertension, diabetes, and smoking. For women with earlier surgical menopause in particular, monitoring cognitive changes over time could provide more information than relying on a single baseline assessment. None of this changes existing guidance on hormone therapy, which continues to be guided by symptom management and individualized risk-benefit discussion rather than cognitive protection, but it does suggest that reproductive history may be relevant when clinicians consider a patient’s longer-term brain health and cardiovascular risk profile.

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.